カテゴリ： QYResearch, 世界, 環境/エネルギー

壊死性自己免疫性筋炎の世界市場2025年：ステロイド剤、免疫抑制剤、その他

■ 英語タイトル：Global Necrotizing Autoimmune Myositis Market Research Report 2025

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8828）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8828
■ 発行日：2025年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：81
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥417,600見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥626,400見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥835,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[壊死性自己免疫性筋炎の世界市場2025年：ステロイド剤、免疫抑制剤、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は壊死性自己免疫性筋炎のグローバル市場について調査・分析し、世界の壊死性自己免疫性筋炎市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ステロイド剤、免疫抑制剤、その他）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、GlaxoSmithKline plc、Dr. Reddy's Laboratories、Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)、Hetero Drugs Limited、AbbVie Inc.、Teva Pharmaceutical Industries、Novartis AGなどが含まれています。壊死性自己免疫性筋炎のグローバル市場は、2024年にXXX米ドル、2031年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。貿易戦争とロシア・ウクライナ戦争の影響は、壊死性自己免疫性筋炎市場規模を算出する際に考慮しました。

・壊死性自己免疫性筋炎市場の概要
- 壊死性自己免疫性筋炎の種類別セグメント
- 世界の壊死性自己免疫性筋炎市場規模：タイプ別分析（ステロイド剤、免疫抑制剤、その他）
- 壊死性自己免疫性筋炎の用途別セグメント
- 世界の壊死性自己免疫性筋炎市場規模：用途別分析（病院、薬局、その他）
- 世界の壊死性自己免疫性筋炎市場規模予測（2020年-2031年）

・壊死性自己免疫性筋炎市場の成長トレンド
- 壊死性自己免疫性筋炎の地域別市場規模（2020年-2031年）
- 壊死性自己免疫性筋炎市場ダイナミクス
- 壊死性自己免疫性筋炎の業界動向
- 壊死性自己免疫性筋炎市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：ステロイド剤、免疫抑制剤、その他
- 世界の壊死性自己免疫性筋炎のタイプ別市場規模（2020年-2025年）
- 世界の壊死性自己免疫性筋炎のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、薬局、その他
- 世界の壊死性自己免疫性筋炎の用途別市場規模（2020年-2025年）
- 世界の壊死性自己免疫性筋炎の用途別市場規模（2024年-2029年）

・壊死性自己免疫性筋炎の地域別市場規模
- 北米の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- 米国の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- ヨーロッパの壊死性自己免疫性筋炎市場規模（2020年-2031年）
- アジア太平洋の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- 中国の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- 日本の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- 韓国の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- インドの壊死性自己免疫性筋炎市場規模（2020年-2031年）
- オーストラリアの壊死性自己免疫性筋炎市場規模（2020年-2031年）
- 中南米の壊死性自己免疫性筋炎市場規模（2020年-2031年）
- 中東・アフリカの壊死性自己免疫性筋炎市場規模（2020年-2031年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
GlaxoSmithKline plc、Dr. Reddy's Laboratories、Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)、Hetero Drugs Limited、AbbVie Inc.、Teva Pharmaceutical Industries、Novartis AG

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Necrotizing Autoimmune Myositis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of % during the forecast period 2025-2031. The influence of trade war and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2023 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2023 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Necrotizing Autoimmune Myositis in Hospital is estimated to increase from $ million in 2023 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The key global companies of Necrotizing Autoimmune Myositis include GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries and Novartis AG, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Necrotizing Autoimmune Myositis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Necrotizing Autoimmune Myositis.
The Necrotizing Autoimmune Myositis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Necrotizing Autoimmune Myositis market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Necrotizing Autoimmune Myositis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
GlaxoSmithKline plc
Dr. Reddy’s Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG
Segment by Type
Steroid Drugs
Immunosuppressant
Others
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Necrotizing Autoimmune Myositis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Steroid Drugs
1.2.3 Immunosuppressant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Necrotizing Autoimmune Myositis Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Necrotizing Autoimmune Myositis Market Perspective (2020-2031)
2.2 Necrotizing Autoimmune Myositis Growth Trends by Region
2.2.1 Global Necrotizing Autoimmune Myositis Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Necrotizing Autoimmune Myositis Historic Market Size by Region (2020-2025)
2.2.3 Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2026-2031)
2.3 Necrotizing Autoimmune Myositis Market Dynamics
2.3.1 Necrotizing Autoimmune Myositis Industry Trends
2.3.2 Necrotizing Autoimmune Myositis Market Drivers
2.3.3 Necrotizing Autoimmune Myositis Market Challenges
2.3.4 Necrotizing Autoimmune Myositis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue
3.1.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue (2020-2025)
3.1.2 Global Necrotizing Autoimmune Myositis Revenue Market Share by Players (2020-2025)
3.2 Global Necrotizing Autoimmune Myositis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Necrotizing Autoimmune Myositis Revenue
3.4 Global Necrotizing Autoimmune Myositis Market Concentration Ratio
3.4.1 Global Necrotizing Autoimmune Myositis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Necrotizing Autoimmune Myositis Revenue in 2022
3.5 Necrotizing Autoimmune Myositis Key Players Head office and Area Served
3.6 Key Players Necrotizing Autoimmune Myositis Product Solution and Service
3.7 Date of Enter into Necrotizing Autoimmune Myositis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Necrotizing Autoimmune Myositis Breakdown Data by Type
4.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Type (2020-2025)
4.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2026-2031)
5 Necrotizing Autoimmune Myositis Breakdown Data by Application
5.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Application (2020-2025)
5.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Necrotizing Autoimmune Myositis Market Size (2020-2031)
6.2 North America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
6.4 North America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Necrotizing Autoimmune Myositis Market Size (2020-2031)
7.2 Europe Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
7.4 Europe Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Necrotizing Autoimmune Myositis Market Size (2020-2031)
8.2 Asia-Pacific Necrotizing Autoimmune Myositis Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2020-2025)
8.4 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Necrotizing Autoimmune Myositis Market Size (2020-2031)
9.2 Latin America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
9.4 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Necrotizing Autoimmune Myositis Market Size (2020-2031)
10.2 Middle East & Africa Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2020-2025)
10.4 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Detail
11.1.2 GlaxoSmithKline plc Business Overview
11.1.3 GlaxoSmithKline plc Necrotizing Autoimmune Myositis Introduction
11.1.4 GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.1.5 GlaxoSmithKline plc Recent Development
11.2 Dr. Reddy’s Laboratories
11.2.1 Dr. Reddy’s Laboratories Company Detail
11.2.2 Dr. Reddy’s Laboratories Business Overview
11.2.3 Dr. Reddy’s Laboratories Necrotizing Autoimmune Myositis Introduction
11.2.4 Dr. Reddy’s Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.2.5 Dr. Reddy’s Laboratories Recent Development
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Detail
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Introduction
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Detail
11.4.2 Hetero Drugs Limited Business Overview
11.4.3 Hetero Drugs Limited Necrotizing Autoimmune Myositis Introduction
11.4.4 Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.4.5 Hetero Drugs Limited Recent Development
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Detail
11.5.2 AbbVie Inc. Business Overview
11.5.3 AbbVie Inc. Necrotizing Autoimmune Myositis Introduction
11.5.4 AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.5.5 AbbVie Inc. Recent Development
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Detail
11.6.2 Teva Pharmaceutical Industries Business Overview
11.6.3 Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Introduction
11.6.4 Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.6.5 Teva Pharmaceutical Industries Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Necrotizing Autoimmune Myositis Introduction
11.7.4 Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2020-2025)
11.7.5 Novartis AG Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Steroid Drugs
Table 3. Key Players of Immunosuppressant
Table 4. Key Players of Others
Table 5. Global Necrotizing Autoimmune Myositis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Necrotizing Autoimmune Myositis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Necrotizing Autoimmune Myositis Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Necrotizing Autoimmune Myositis Market Share by Region (2020-2025)
Table 9. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Necrotizing Autoimmune Myositis Market Share by Region (2026-2031)
Table 11. Necrotizing Autoimmune Myositis Market Trends
Table 12. Necrotizing Autoimmune Myositis Market Drivers
Table 13. Necrotizing Autoimmune Myositis Market Challenges
Table 14. Necrotizing Autoimmune Myositis Market Restraints
Table 15. Global Necrotizing Autoimmune Myositis Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Necrotizing Autoimmune Myositis Market Share by Players (2020-2025)
Table 17. Global Top Necrotizing Autoimmune Myositis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Necrotizing Autoimmune Myositis as of 2022)
Table 18. Ranking of Global Top Necrotizing Autoimmune Myositis Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Necrotizing Autoimmune Myositis Revenue (CR5 and HHI) & (2020-2025)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Necrotizing Autoimmune Myositis Product Solution and Service
Table 22. Date of Enter into Necrotizing Autoimmune Myositis Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Necrotizing Autoimmune Myositis Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Necrotizing Autoimmune Myositis Revenue Market Share by Type (2020-2025)
Table 26. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Necrotizing Autoimmune Myositis Revenue Market Share by Type (2026-2031)
Table 28. Global Necrotizing Autoimmune Myositis Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Necrotizing Autoimmune Myositis Revenue Market Share by Application (2020-2025)
Table 30. Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Necrotizing Autoimmune Myositis Revenue Market Share by Application (2026-2031)
Table 32. North America Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Necrotizing Autoimmune Myositis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Necrotizing Autoimmune Myositis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2026-2031) & (US$ Million)
Table 47. GlaxoSmithKline plc Company Detail
Table 48. GlaxoSmithKline plc Business Overview
Table 49. GlaxoSmithKline plc Necrotizing Autoimmune Myositis Product
Table 50. GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 51. GlaxoSmithKline plc Recent Development
Table 52. Dr. Reddy's Laboratories Company Detail
Table 53. Dr. Reddy's Laboratories Business Overview
Table 54. Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Product
Table 55. Dr. Reddy's Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 56. Dr. Reddy's Laboratories Recent Development
Table 57. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Detail
Table 58. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
Table 59. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Product
Table 60. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 61. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
Table 62. Hetero Drugs Limited Company Detail
Table 63. Hetero Drugs Limited Business Overview
Table 64. Hetero Drugs Limited Necrotizing Autoimmune Myositis Product
Table 65. Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 66. Hetero Drugs Limited Recent Development
Table 67. AbbVie Inc. Company Detail
Table 68. AbbVie Inc. Business Overview
Table 69. AbbVie Inc. Necrotizing Autoimmune Myositis Product
Table 70. AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 71. AbbVie Inc. Recent Development
Table 72. Teva Pharmaceutical Industries Company Detail
Table 73. Teva Pharmaceutical Industries Business Overview
Table 74. Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Product
Table 75. Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 76. Teva Pharmaceutical Industries Recent Development
Table 77. Novartis AG Company Detail
Table 78. Novartis AG Business Overview
Table 79. Novartis AG Necrotizing Autoimmune Myositis Product
Table 80. Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2020-2025) & (US$ Million)
Table 81. Novartis AG Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Necrotizing Autoimmune Myositis Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 2. Global Necrotizing Autoimmune Myositis Market Share by Type: 2022 VS 2029
Figure 3. Steroid Drugs Features
Figure 4. Immunosuppressant Features
Figure 5. Others Features
Figure 6. Global Necrotizing Autoimmune Myositis Market Size Comparison by Application (2025-2031) & (US$ Million)
Figure 7. Global Necrotizing Autoimmune Myositis Market Share by Application: 2022 VS 2029
Figure 8. Hospital Case Studies
Figure 9. Pharmacy Case Studies
Figure 10. Others Case Studies
Figure 11. Necrotizing Autoimmune Myositis Report Years Considered
Figure 12. Global Necrotizing Autoimmune Myositis Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Necrotizing Autoimmune Myositis Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Necrotizing Autoimmune Myositis Market Share by Region: 2022 VS 2029
Figure 15. Global Necrotizing Autoimmune Myositis Market Share by Players in 2024
Figure 16. Global Top Necrotizing Autoimmune Myositis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Necrotizing Autoimmune Myositis as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Necrotizing Autoimmune Myositis Revenue in 2024
Figure 18. North America Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 20. United States Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 24. Germany Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Necrotizing Autoimmune Myositis Market Share by Region (2020-2031)
Figure 32. China Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 40. Mexico Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Necrotizing Autoimmune Myositis Market Share by Country (2020-2031)
Figure 44. Turkey Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Necrotizing Autoimmune Myositis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. GlaxoSmithKline plc Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 47. Dr. Reddy's Laboratories Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 48. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 49. Hetero Drugs Limited Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 50. AbbVie Inc. Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 51. Teva Pharmaceutical Industries Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 52. Novartis AG Revenue Growth Rate in Necrotizing Autoimmune Myositis Business (2020-2025)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed

※参考情報

壊死性自己免疫性筋炎は、自己免疫疾患の一種であり、主に筋肉組織に影響を及ぼす病態です。この疾病は、筋肉細胞の破壊と炎症を引き起こす自己抗体によって特徴付けられます。本稿では、壊死性自己免疫性筋炎の定義、特徴、種類、診断と治療の方法、および関連技術について詳しく説明します。

壊死性自己免疫性筋炎は、主に筋肉の炎症と壊死を伴う自己免疫疾患であり、一般的に20歳から70歳の成人に発症しますが、特に高齢者や女性に多く見られます。この病態では、免疫系が誤って自分自身の筋肉細胞を攻撃し、これにより筋肉痛、筋力低下、筋肉の萎縮などの症状が現れます。急激に進行することがあるため、早期の診断と適切な治療が重要です。

この疾患の特徴として、通常は筋力の低下があげられます。患者は、手足を動かすことや、物を持つこと、日常生活に必要な動作が困難になることがあります。また、筋肉の痛みやけいれん、歩行が困難になることもあります。さらに、全身症状として疲労感や発熱を伴うこともあります。時には、皮膚症状や内臓が侵されることもあります。

壊死性自己免疫性筋炎にはいくつかのタイプがあります。代表的なものとしては、特定の自己抗体が関連している「抗ミオシン抗体陽性型」や「抗トロポミオシン抗体陽性型」、また他の自己免疫疾患と関連することが多い「重症筋無力症合併型」などがあります。それぞれの型は、自己抗体の種類によって異なる病態の展開を示し、治療方針にも影響を及ぼします。

診断は、臨床症状の確認と共に、血液検査や筋生検、画像診断によって行われます。特に血液中の筋酵素（CK値）や自己抗体の存在を評価することは重要です。筋生検では、筋肉組織の病理学的変化を確認することで、他の疾患との鑑別が行われます。CTやMRIを用いることで筋肉の状態や炎症の程度を視覚的に評価することもあります。

治療方法には、主に免疫抑制薬が使用されます。コルチコステロイドやメトトレキサート、リツキシマブといった薬剤が一般的です。これらは、免疫系の過剰な反応を抑え、筋肉の炎症を軽減することを目的としています。また、リハビリテーションも重要であり、筋力や可動域を回復させるための運動療法が取り入れられることがあります。早期に介入することによって、筋肉の損傷を最小限に抑えることが可能です。

さらに、壊死性自己免疫性筋炎の研究は進んでおり、新たな治療法や診断技術の開発が期待されています。バイオマーカーの研究が進む中で、患者ごとに異なる病態をより正確に捉えるための手法が模索されています。特に、遺伝的要因や環境因子が病気の発症に与える影響についての研究が進行中であり、これにより個々の患者に適した治療法の開発が期待されています。

壊死性自己免疫性筋炎は、専門的な知識を要する病態であり、患者の生活の質を著しく低下させることがあります。そのため、医療チームが一丸となって管理し、患者に最適な治療を提供することが重要です。また、患者や家族に対して病態や治療について十分な説明を行い、理解を深めてもらうことも大切です。

最後に、壊死性自己免疫性筋炎の患者は、定期的なフォローアップが必要です。疾病の進行や治療の効果を評価するためには、継続的な医療管理が不可欠です。早期発見と適切な治療によって、生活の質の向上を図ることが可能であり、患者が自立した生活を送るためのサポートを行うことが、医療関係者の重要な責務であります。このように、壊死性自己免疫性筋炎は複雑な自己免疫疾患でありますが、適切な知識と治療によって管理可能な病態であると言えるでしょう。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 免疫調整剤のグローバル市場：免疫抑制剤、免疫刺激剤
  • 多発性硬化症治療薬のグローバル市場：免疫調節薬、免疫抑制剤
  • 血管炎治療のグローバル市場（2021〜2031）：生物製剤、コルチコステロイド・免疫抑制剤
  • 免疫学のグローバル市場（2022年-2029年）：モノクローナル抗体、免疫抑制剤、融合タンパク質、その他
  • 犬アトピー性皮膚炎のグローバル市場：グルココルチコイド、免疫抑制剤、モノクローナル抗体、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8828 )"壊死性自己免疫性筋炎の世界市場2025年：ステロイド剤、免疫抑制剤、その他" (英文：Global Necrotizing Autoimmune Myositis Market Research Report 2025)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。